Topics I've Started

So the results for the ASC-J9 cream have been posted. For those who don't know, AndroScience developed a cream that has a molecule that block androgen receptors. So in other words, the sebaceous glands would be blocked from getting androgens to stimulate them in producing more oil.

So the highest dose tested was the only one to give significant results, with a 45% reduction of lesions, in comparison to the control cream. Also, more people went down in their acne scale, total of 28, in comparison to the control which was 23.

This cream needs further improvement in my opinion, because is nowhere near a miracle. It sounds just as effective as retinols, so it probably has to be paired with other topicals. This cream is nowhere near the effectiveness of accutane, and I think its because you have to remember that accutane not only lowers oil production significantly, but it also has other factors, like controls skin shedding and it's antiinflammatory. I will stick with accutane.

May 30, 2012 — The US Food and Drug Administration (FDA) has approved cip-isotretinoin, a novel, patented brand formulation of the currently available acne medication isotretinoin, Cipher Pharmaceuticals announced this week.Cip-isotretinoin is indicated for the treatment of severe recalcitrantnodular acne. It is expected to be available in the United States in the fourth quarter of 2012 under the brand name Absorica.Better AbsorptionIn comparison with current isotretinoin formulations on the market, cip-isotretinoin uses Cipher's patented Lidosedrug delivery system, which the company says offers more precise, consistent, and uniform drug delivery than currently available isotretinoin.In phase 1 clinical studies, cip-isotretinoin demonstrated a "significant competitive advantage in the treatment of severe, recalcitrant nodular acne," the company notes on its Web site."A major issue for existing isotretinoin products is patient compliance, as the active ingredient should be taken with a high-fat meal to ensure consistent absorption," the company explains. "Teenage eating habits are typically irregular compared to working-age adults."It continues, "Cip-Isotretinoin has been proven to provide a more consistent absorption under fed and fasted conditions, compared to existing isotretinoin products that exhibit a 65% reduction in absorption under fasted conditions. Cip-Isotretinoin offers more consistent absorption day-in and day-out over the course of a typical 3- to 5-month treatment period."In 2011, Cipher completed a pivotal phase 3 randomized double-blinded trial comparing the safety profile of cip-isotretinoin with an FDA-approved, commercially available isotretinoin product. The safety, efficacy, and population pharmacokinetic data generated from this study formed the basis of the company's regulatory approvalapplication in the United States.Cip-isotretinoin is a "valuable option for the dermatologist and patients who need treatment for severe recalcitrant nodular acne," Venkat Krishnan, senior vice president and regional director, Americas, for Ranbaxy Laboratories Inc, said in a statement. Cipher Pharmaceuticals is partnering with Ranbaxy Laboratories Inc to launch the product in the US market.Cip-isotretinion is currently under review by Health Canada, and Cipher Pharmaceuticals says it anticipates a decision in the first quarter of 2013.<a href="http://www.medscape....warticle/764748

So my doctor has decided to put me on a low dose treatment, even though my acne was moderately severe. I am 99% clear now, but if I keep going on this dosage he wants me to take, I will be taken accutane for a total of a year and two months. I don't think this is normal, and with such a low dose, am I even going to get long term remission. should i get a second opinion??